New real-time PCR rapid test for detection of four STI
First Vivalytic test in cooperation with development partner BioGX
Positive test results available within an hour directly at the point of care
Waiblingen – Bosch Healthcare Solutions has received CE-label for the new Vivalytic MG, MH, UP/UU, developed in partnership with BioGX, a US-based global molecular diagnostics company. The test is now available as part of the Vivalytic analyser test portfolio and can thus be used directly at the point of care. This real-time PCR rapid test can detect four pathogens of sexually transmitted infections (STIs): Mycoplasma genitalium (MG), Mycoplasma hominis (MH), Ureaplasma parvum (UP), and Ureaplasma urealyticum (UU). After taking the sample and starting the analysis, a positive result is available in as little as an hour, making the test particularly suitable for use in direct patient care at doctors’ offices and clinics. Here, it can enable STI differential diagnosis directly at the point of sampling without delays due to transportation or logistics. For example, the test can detect in case of infectious urethritis (non-gonorrheal urethritis, NGU) (1), if one of the four pathogens is responsible for the infection. However, rapid diagnosis also helps to counteract the further spread of STI pathogens. The Vivalytic MG, MH, UP/UU test saves a lot of time compared to diagnostics by cultivation of the pathogenic germs. In the case of MH, UP, and UU, cultivation can take one to three days, and up to six months for MG (2).